Based on results of this pilot study, an in vivo experiment was performed to ascertain if Vβ-family-specific targeting antibody must work in conjunction with CD64 IR T cells, rather than untransduced T cells, to produce a significant anti-tumor effect. The gene discussed is FCGR1A; the disease is neoplasm.